Patient description: A 46-year-old man presents with dizziness and frequent headaches. He has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus and is physically active. The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively. His fasting glucose and triglyceride levels (85 and 158 mg/dL, resp.) were within normal limits. The patient reported no use of lipid-lowering medications. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull. Ultrasonography of the carotid arteries, revealed severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. For the LICA, the peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values were 208.5 cm/s and 54.5 cm/s, respectively; RICA PSV was 91.72 cm/s and RICA EDV was 37.37 cm/s. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carotid Artery Disease Stroke Prevention ≥ 18 years old; 2. for carotid artery revascularization; 3. A significant stenosis in symptomatic patients with ≥ 50% Diameter Stenosis (%DS) or asymptomatic ≥ 80 %DS as defined by angiography. Symptomatic is defined as a carotid artery stenosis associated with ipsilateral TIA, amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment. 4. Suitable clinical conditions to perform DW-MRI. 5. Written informed consent as approved by the Ethics Committee of the respective clinical site  Female with childbearing potential without a negative pregnancy test. 2. Life-expectancy less than 6 months. 3. Underlying disease of the carotid artery other than atherosclerosis (e.g. vasculitis, traumatic dissection, fibromuscular dysplasia). 4. Prior stenting in the target vessel; 5. Patients with chronic or re-current atrial fibrillation. 6. Patient has had a Myocardial Infarction within 72 hours prior to the procedure. 7. Patient experienced a stroke within 4 weeks prior to the procedure. 8. History of severe disabling stroke according to the modified Rankin scale > 4. 9. Severe renal failure (serum creatinine > 2.0 mg/dL). 10. Severe peripheral arterial occlusive disease, which might impede a safe introduction of a 9F-sheath for the use of a Mo.Ma-device. 11. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Statins, Heparin, Nitinol, contrast agents (that cannot be adequately pre-medicated). 12. Patient currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the study endpoints. 13. Any planned major surgery within 30 days after the study procedure. 14. In the investigators opinion patient has a severe co-morbid condition(s) that could limit the ability to participate in the study. Angiographic Totally occluded internal carotid artery considered as the target vessel. 16. Multiple internal carotid artery stenoses or lesion longer than 4 cm (whichever occurs) that cannot be covered by one (1) stent. 17. Severe ostial stenosis of the common carotid artery. 18. The presence of ipsilateral intracranial stenosis that requires treatment. 19. Contralateral occlusion of the internal carotid arteries associated with a poor collateral flow through the circle of Willis. 20. An aortic arch anatomical complexity that may preclude the safe placement of the Mo.Ma device including particularly, the impossibility to navigate a stiff guide wire into the external carotid artery